187 related articles for article (PubMed ID: 20836675)
1. Risk stratification in extranodal natural killer/T-cell lymphoma.
Kohrt H; Lee M; Advani R
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1395-405. PubMed ID: 20836675
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis and management of natural killer-cell malignancies.
Ishida F; Kwong YL
Expert Rev Hematol; 2010 Oct; 3(5):593-602. PubMed ID: 21083476
[TBL] [Abstract][Full Text] [Related]
3. Extranodal natural killer/T-cell lymphoma: advances in the management.
Jaccard A; Hermine O
Curr Opin Oncol; 2011 Sep; 23(5):429-35. PubMed ID: 21743325
[TBL] [Abstract][Full Text] [Related]
4. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
[TBL] [Abstract][Full Text] [Related]
5. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.
Yamaguchi M; Kwong YL; Kim WS; Maeda Y; Hashimoto C; Suh C; Izutsu K; Ishida F; Isobe Y; Sueoka E; Suzumiya J; Kodama T; Kimura H; Hyo R; Nakamura S; Oshimi K; Suzuki R
J Clin Oncol; 2011 Nov; 29(33):4410-6. PubMed ID: 21990393
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
8. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
[TBL] [Abstract][Full Text] [Related]
9. [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
Cui XZ; Wang HQ; Liu XM; Zhang HL; Li W
Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):609-11. PubMed ID: 18246818
[TBL] [Abstract][Full Text] [Related]
10. Practical management of natural killer/T-cell lymphoma.
Tse E; Kwong YL
Curr Opin Oncol; 2012 Sep; 24(5):480-6. PubMed ID: 22691924
[TBL] [Abstract][Full Text] [Related]
11. Extranodal natural killer/T cell lymphoma: we should and we can do more.
Ying Z; Zhu J
Chin Clin Oncol; 2015 Mar; 4(1):12. PubMed ID: 25841719
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
[TBL] [Abstract][Full Text] [Related]
13. Concurrent chemoradiotherapy for limited-stage extranodal natural killer/t-cell lymphoma, nasal type.
Shimada K; Suzuki R
J Clin Oncol; 2010 May; 28(14):e229; author reply e230. PubMed ID: 20351319
[No Abstract] [Full Text] [Related]
14. Salvage treatment improved survival of patients with relapsed extranodal natural killer/t-cell lymphoma, nasal type.
Zhang XX; Xie CH; Xu Y; Deng D; Zhao YH; Zou BW; Zhou L; Li M; Wang J; Liu WP; Huang MJ
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):747-52. PubMed ID: 19304409
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
[TBL] [Abstract][Full Text] [Related]
16. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
Liu X; Wang B; Ma X; Guo Y
Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
[TBL] [Abstract][Full Text] [Related]
17. Combined immune checkpoint blockade and radiotherapy induces durable remission in relapsed natural killer/T-cell lymphoma: a case report and review of the literature.
McGehee E; Patel H; Pearson C; Clements K; Jaso JM; Chen W; Callan A; Desai N; Ramakrishnan Geethakumari P
J Med Case Rep; 2021 Apr; 15(1):221. PubMed ID: 33926575
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
19. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type.
Wu X; Li P; Zhao J; Yang X; Wang F; Yang YQ; Fang F; Xu Y; Zhang H; Wang WY; Yi C
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):619-25. PubMed ID: 18790372
[TBL] [Abstract][Full Text] [Related]
20. Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type.
Yamaguchi M; Suzuki R; Oguchi M
Blood; 2018 Jun; 131(23):2528-2540. PubMed ID: 29602763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]